Winton Group LTD I Teos Therapeutics, Inc. Transaction History

Winton Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$10.95 - $14.6 $232,369 - $309,826	21,221 Added 173.77%	33,433 $366,000
Q2 2023 Aug 14, 2023	SELL	$12.93 - $18.05 $80,398 - $112,234	-6,218 Reduced 33.74%	12,212 $161,000
Q1 2023 May 12, 2023	SELL	$13.02 - $22.62 $14,282 - $24,814	-1,097 Reduced 5.62%	18,430 $250,000
Q4 2022 Feb 14, 2023	SELL	$17.77 - $21.6 $522,011 - $634,521	-29,376 Reduced 60.07%	19,527 $381,000
Q3 2022 Nov 10, 2022	SELL	$18.6 - $27.25 $62,514 - $91,587	-3,361 Reduced 6.43%	48,903 $932,000
Q2 2022 Aug 10, 2022	BUY	$16.57 - $35.1 $677,431 - $1.43 Million	40,883 Added 359.22%	52,264 $1.08 Million
Q1 2022 May 11, 2022	BUY	$31.92 - $47.45 $363,281 - $540,028	11,381 New	11,381 $366,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.